Podcasts about viatris

This podcast has been funded by an educational grant from Viatris. Systemic lupus erythematosus (SLE) is a complex, heterogeneous disease shaped by dysregulated immune pathways, variable organ involvement, and substantial patient burden. In this educational podcast, Anca Askanase explores how a deeper understanding of SLE immunology can help rheumatologists contextualize disease activity, evolving research, and guideline-based care. Topics covered: Key immune pathways involved in SLE pathophysiology, including innate and adaptive immune dysregulation  How pathway biology may help explain clinical heterogeneity and differences in disease activity between patients  What rheumatologists should consider when interpreting emerging pathway-based research and cross-disease immunology concepts  How current guideline-based care frames treatment goals, patient burden, and the evolving focus on remission in SLE  Speakers Anca D. Askanase, Chair, Department of Medicine, and Chief, Division of Rheumatology, Hospital for Special Surgery, New York, USA

This episode covers: Cardiology This Week: A concise summary of recent studies Transcatheter treatment of tricuspid regurgitation Carcinoid heart disease Milestones: MADIT-II Trial Host: Wilfried Mullens Guests: Stephan Baldus, Heidi Connolly and Konstantinos Koskinas Want to watch that episode? Go to: https://esc365.escardio.org/event/2560 Want to watch that extended interview on transcatheter treatment of tricuspid regurgitation, go to: https://esc365.escardio.org/event/2560?resource=interview   Disclaimer  ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina, Heidi Connolly, Nicolle Kraenkel and Wilfried Mullens have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. Stephan Baldus has declared to have potential conflicts of interest to report: research grant from Abbott, lecture fees from Abbott and Edwards. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Wilfried Mullens Guest: Stephan Baldus Want to watch that extended interview, go to: https://esc365.escardio.org/event/2560?resource=interview Want to watch that entire episode? Go to: https://esc365.escardio.org/event/2560   Disclaimer ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel and Wilfried Mullens have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. Stephan Baldus has declared to have potential conflicts of interest to report: research grant from Abbott, lecture fees from Abbott and Edwards. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This is Part 1 of a five-part miniseries on Tim Griesheimer's life. Tim is by far one of the most popular guests we've had on the show, so this series dives even deeper into his life featuring new stories about gang life, prison, identity, trauma, and redemption. In this episode, Tim shares the early chapters of his life, from growing up in an abusive household to finding acceptance in the streets, gang culture, and eventually prison. Tim opens up about what it was like being white while running with mostly Black friends and Blood gang members, how racial dynamics differed between Ohio and Texas, and the controversy around using the n-word. He also describes childhood violence, early crime, carrying guns as a kid, shootouts, and how he became drawn to the outlaw lifestyle before his first prison sentence. Topics include: -Growing up in Ohio and Texas -Childhood abuse and street life -Being white around Blood gang members -Saying the n-word and facing consequences -Early gun violence and shootouts -Racial tension in Texas -First experiences with prison politics -Finding identity through crime and gang culture Go Support Tim! IG: https://www.instagram.com/tattoos_bykriminalkustoms/ This Episode Is #Sponsored By The Following: Hims! To get simple, online access to personalized, affordable care for ED, Hair Loss, Weight Loss, and more, visit https://hims.com/connect Prescription required. See website for details and important safety information. Sildenafil is the generic version of Viagra®. Viagra® is a registered trademark of Viatris Specialty LLC. Hims is not affiliated with or endorsed by Viatris. Join The Patreon For Bonus Content! https://www.patreon.com/theconnectshow 00:00 From a Troubled Home to the Streets 01:01 Introducing Tim Griesheimer's Story 04:47 Connecting with People and Early Social Traits 07:09 Nature vs. Nurture and Developing an Outlaw Mentality 10:27 Embracing the Streets: Stealing and Early Crimes 13:01 Fighting, Survival, and Street Cred 17:08 Shootouts and Guns at a Young Age 21:12 Gang Affiliations: Bloods, Crips, and Neighborhood Politics 25:48 This Episode Is Sponsored By Hims 27:38 Reflecting on Gang Life, Family Bonds, and Military Ambitions 33:13 Childhood Abuse and Family Trauma 36:50 Violence at Home and Resentment Toward Parents 41:13 Cycles of Abuse: Family History 43:14 Moving Between States & Unstable Upbringing 45:27 Culture Shock: Racial Dynamics in Texas vs. Ohio 48:00 Experiencing Prejudice from Both Black and White Communities 50:01 First Time Going to Prison – Facing Reality 54:01 Arrival at the Most Dangerous Texas Prison 56:11 Navigating Prison Politics and Racial Pressure Learn more about your ad choices. Visit podcastchoices.com/adchoices

Gordon Bethwaite, head of marketing of eye care at Viatris, joins the Eye on Innovation podcast with host Carey Powers, M.B.A. to discuss Viatris' footprint and impact on ophthalmology on a global scale. Bethwaite shares details on the company's overall strategic vision for eye care, their fifth anniversary, and how it handles the “noisy category” that is dry eye. In this episode, learn about: Viatris' acquisitions and license agreements with different companiesWhat Tyrvaya brings to the table for clinicians and patientsHow Viatris is tackling unmet marketsWhat innovation means to Viatris in the context of ophthalmology RESOURCES: Carey Powers: https://ois.net/carey-powers/     Gordon Bethwaite: https://ois.net/gordon-bethwaite/ 

Former federal inmate Eric King joins to expose what life is really like inside ADX Florence, America's most notorious supermax prison. After being sentenced to 10 years for firebombing a politician's office in 2014, King says he endured brutal treatment in federal custody, including beatings, starvation, solitary confinement, four-point restraints, and years of communication restrictions. In this episode, Eric opens up about his radicalization in Kansas City, the Ferguson protests, his federal case, surviving violent prison politics, fighting a guard in self-defense, winning at trial, and later being sent to ADX Florence in what he believes was retaliation. He also explains the psychological toll of extreme isolation, the myths surrounding ADX, how prisoners communicate inside, and what it took to rebuild his life after release. Eric is the author of A Clean Hell: Anarchy and Abolition Inside America's Most Notorious Dungeon, a firsthand account of survival, resistance, and humanity inside the federal prison system. Topics include: -Eric King's childhood and political awakening -Ferguson, direct action, and his federal charges -Violence, solitary confinement, and prison retaliation -Life inside ADX Florence -The psychological effects of extreme isolation -Reentry, trauma, family, and healing after prison Go Support Eric! Book: https://pmpress.org/index.php?l=product_detail&p=1872 IG: https://www.instagram.com/supportericking/ This Episode Is #Sponsored By The Following: Hims! To get simple, online access to personalized, affordable care for ED, Hair Loss, Weight Loss, and more, visit https://hims.com/connect Prescription required. See website for details and important safety information. Sildenafil is the generic version of Viagra®. Viagra® is a registered trademark of Viatris Specialty LLC. Hims is not affiliated with or endorsed by Viatris. Cash App! Download Cash App Today: https://capl.onelink.me/vFut/1ekoiacn #CashAppPod. Cash App is a financial services platform, not a bank. Banking services provided by Cash App's bank partner(s). Prepaid debit cards issued by Sutton Bank, Member FDIC. See terms and conditions at https://cash.app/legal/us/en-us/card-agreement. Cash App Green, overdraft coverage, borrow, cash back offers and promotions provided by Cash App, a Block, Inc. brand. Visit http://cash.app/legal/podcast for full disclosures. Join The Patreon For Bonus Content! https://www.patreon.com/theconnectshow 00:00 Eric King Introduction 02:00 Eric's Early Life & Radicalization 06:00 Growing Up: Crime, Poverty, and Activism 12:00 Losing Faith & Early Legal Troubles 18:00 Protest, Ferguson, and Political Activism 21:06 This Episode Is Sponsored By Hims 22:41 The Crime: Ferguson Response & Arrest 29:00 Prison: First Experiences & Racial Politics 34:00 Surviving Prison Culture & Targeting 40:00 Abuse by Guards & Florence Medium Incident 45:42 This Episode Is Sponsored By Cash App 47:00 Torture, Four-Point Room & Transfer Hell 53:00 Isolation, Violence, and Solitary Life 01:00:00 Fighting Back: Resistance & Prison Protests 01:14:00 Second Trial: Self-Defense, Winning in Court 01:20:00 ADX Florence: Punishment & Reprisal Transfers 01:28:00 Arriving at ADX: Conditions and Isolation 01:37:00 ADX Daily Life & Psychological Impact 01:49:00 Punitive System, Corruption, and Quota Reality 01:56:00 Surviving Isolation: Mental Discipline & Gratitude 02:00:00 Reentry: Life After Prison & Its Challenges 02:06:00 Reflection: Regrets, Growth, and Activism Now 02:12:00 ADX Realities, Mythbusting & Book Release 02:18:00 ADX Procedures, High-Profile Inmates & Closing Learn more about your ad choices. Visit podcastchoices.com/adchoices

This episode covers: Cardiology This Week: A concise summary of recent studies The heart in high altitude Mitral annular disjunction Mythbusters: Weekend mortality Host: Rick Grobbee Guests: JP Carpenter, Kristina Haugaa, Silvia Ulrich Want to watch that episode? Go to: https://esc365.escardio.org/event/2563 Want to watch that extended interview on mitral annular disjonction, go to: https://esc365.escardio.org/event/2563?resource=interview   Disclaimer ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina, Rick Grobbee, Kristina Haugaa, Nicolle Kraenkel and Silvia Ulrich have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.  Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Rick Grobbee Guest: Kristina Haugaa Want to watch that extended interview on https://esc365.escardio.org/event/2563?resource=interview Go to: Want to watch that episode? Go to: https://esc365.escardio.org/event/2563   Disclaimer ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina, Rick Grobbee, Kristina Haugaa and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Carl Johnson grew up in the streets of Baltimore during the same era HBO was filming The Wire — but while the world watched the show, Carl lived the reality. In this episode, Carl breaks down what The Wire got right and wrong, how Baltimore's open-air drug markets really operate, why the city became such a major heroin and fentanyl hub, and how the collapse of the old street-code changed the game forever. He also opens up about his own past in the streets, his mentor's connection to the real Barksdale family, the violence that shaped Baltimore's reputation, and why fentanyl has made today's drug trade more dangerous than ever. Now out of the game, Carl works in recovery and helps others struggling with addiction through the Baltimore Recovery Alliance. This is a raw, unfiltered look inside one of America's most infamous cities — from someone who survived it and turned his life around. We all watched The Wire. Carl Johnson lived it. Go Support Carl! Recovery Program: https://baltimorerecoveryalliance.com/ This Episode Is #Sponsored By The Following: Hims! To get simple, online access to personalized, affordable care for ED, Hair Loss, Weight Loss, and more, visit https://hims.com/connect Prescription required. See website for details and important safety information. Sildenafil is the generic version of Viagra®. Viagra® is a registered trademark of Viatris Specialty LLC. Hims is not affiliated with or endorsed by Viatris. Join The Patreon For Bonus Content! https://www.patreon.com/theconnectshow 00:00 Meet Carl: From Baltimore Streets to Rehab Counselor 03:45 Intro: The Wire & Baltimore's Unique Drug Market 07:07 Fentanyl Takes Over: Shifts in Baltimore's Drug Trade 13:47 Opiates, Rehab, and Open Air Markets 24:33 How the Drug Game Runs: Corners, Crews, and the Feds 32:14 Baltimore's Changing Landscape: Projects, Gentrification 38:11 This Episode Is Sponsored By Hims 39:47 Abandoned Buildings and Homicide Culture 50:25 Guns, Violence, and Life on the Corners 01:03:41 Life Lessons from the Streets: The Barksdale Legacy 01:11:15 Getting Into the Game: Carl's Early Hustles 01:19:55 Crack vs. Heroin: Insider Secrets, Hustle Hierarchies & Survival 01:34:32 Prison, Probation, and the Turning Point 02:05:31 Rehab, Redemption & Breaking Cycles 02:21:55 Addiction, Policy & Baltimore Recovery Alliance Learn more about your ad choices. Visit podcastchoices.com/adchoices

This episode covers: Cardiology This Week: A concise summary of recent studies Biomarkers in heart failure Digoxin in HFrEF Scientific Highlights from Heart Failure 2026 Host: Wilfried Mullens Guests: Lynne Stevenson, Dirk van Veldhuisen, Theresa McDonagh Want to watch that episode? Go to: https://esc365.escardio.org/event/2565 Disclaimer: ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. A ny views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel, Dirk van Veldhuisen and Lynne Warner Stevenson have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report:Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi.  Theresa McDonagh has declared to have potential conflicts of interest to report: honoraria from Boeringer Ingelheim. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Houston street hustler Jugg sits down with to tell the unbelievable story of how he helped fuel the hydrocodone pill explosion across Louisiana and Texas during the early opioid epidemic. From moving thousands of pills a week out of Houston pain clinics to watching entire communities fall into addiction, Jugg gives a raw firsthand account of the rise of “lean culture,” pill trafficking, doctor shopping, Roxy 30s, and the transition into today's fentanyl crisis. In this interview, Jugg breaks down: -How Houston pain clinics operated during the opioid boom -Making millions trafficking hydrocodone and Roxy pills -Drug culture in Houston and Louisiana in the 2000s -The rise of lean, syrup, and pill addiction -Corrupt clinics, pharmacies, and doctor shopping -Prison, street politics, and surviving the game -Why fentanyl changed everything -His life after prison running trucking businesses and podcasts This is one of the wildest untold stories from the Southern opioid epidemic — straight from someone who lived it. Go Support Jugg! IG: https://www.instagram.com/juggwdh YouTube: @wdhtv2 This Episode Is #Sponsored By Superpower! Head to https://superpower.com and use code CONNECT at checkout for $20 off your membership. Unlock your new health intelligence. 100+ biomarkers. Every year. Detect early signs of 1,000+ conditions. #superpowerpod Hims! To get simple, online access to personalized, affordable care for ED, Hair Loss, Weight Loss, and more, visit https://hims.com/connect Prescription required. See website for details and important safety information. Sildenafil is the generic version of Viagra®. Viagra® is a registered trademark of Viatris Specialty LLC. Hims is not affiliated with or endorsed by Viatris. Hell Fresh! Go to https://hellofresh.com/connect10fm now to Get 10 Free Meals + a Free breakfast for Life! One per box with active subscription. Free meals applied as discount on first box, new subscribers only, varies by plan. That's HelloFresh dot com slash connect10fm to Get 10 Free Meals + free breakfast for Life. Join The Patreon For Bonus Content! https://www.patreon.com/theconnectshow 00:00 Ground Floor of the Pill Game 01:45 Introducing Jugg: Origins & Early Hustle 03:30 Family Ties & Teenage Hustling 05:27 Crack, Pills & Generational Drug Shifts 08:17 The Houston Move & Pain Clinics 11:17 The Hydrocodone Boom 14:07 The Pill Market: Operations & Economics 19:07 Scaling Up: Distribution, Profits & Players 20:45 This Episode Is Sponsored By Superpower 232:29 From Weed to Pills: Business Evolution 28:07 Doctor Shopping & Law Enforcement Crackdown 29:56 This Episode Is Sponsored By Hims 31:38 Switching to Roxys & New Market Challenges 35:37 Effects on Community & Pill Culture 39:34 This Episode Is Sponsored By Hello Fresh 41:05 The Pharmacy System & Regulatory Changes 45:07 Crossing Over: Racial Lines & Generational Impact 48:57 Legal Troubles & Escalating Risks 53:07 Prison Time & Lessons Learned 01:00:17 Fake Pills & Fentanyl Danger 01:04:57 Rap Life vs. Hustle Life 01:10:47 Life after the Game: Trucking & Entrepreneurship 01:14:57 Logistics, Trucking, and Felon-Friendly Careers 01:19:17 Reflections, Community & Closing Thoughts Learn more about your ad choices. Visit podcastchoices.com/adchoices

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we explore China's burgeoning role in the synthetic biology sector, as outlined in a recent article discussing China's strategic focus on biotechnology within its latest five-year plan. This strategy identifies biomanufacturing, particularly synthetic biology and genetic engineering, as pivotal for China's emerging bioeconomy. The nation's approach frames biology as a transformative industrial platform poised to reshape pharmaceuticals, materials science, agriculture, and energy industries. Central to this transformation is DNA synthesis, which allows for the design and manufacture of genetic sequences. As China rapidly expands its synthetic biology capabilities, questions arise about its potential to become an innovation powerhouse, the competitiveness of Chinese firms in DNA synthesis, and geopolitical factors affecting international cooperation and supply chains. Insights from industry leaders highlight China's unique industrialization strengths. The country excels in rapidly scaling technologies due to its ability to mobilize capital, infrastructure, and manufacturing swiftly—a capability that surpasses Europe and the U.S. This aligns with China's national biomanufacturing strategy aimed at developing vast production systems across pharmaceuticals and industrial biotechnology. Beyond sheer manufacturing capacity, China is constructing a comprehensive ecosystem to bolster advanced biotechnology. The nation's development of clinical infrastructure and pharmaceutical manufacturing is noteworthy. China is actively exploring personalized therapies and building regulatory pathways for advanced treatments, signaling a potential shift in global biotech dynamics. Domestically, Chinese companies are developing technology platforms to reduce dependence on imported equipment and Western supply chains. The competitive landscape in DNA synthesis is evolving beyond traditional commodity-versus-innovation narratives, as both Chinese and Western companies pursue similar technological advancements. However, geopolitical tensions complicate collaborations between Chinese and Western firms. Export controls highlight the growing barriers to cooperation. Despite price competitiveness from Chinese DNA synthesis providers, concerns over data security and regulatory risks are prompting some Western buyers to favor suppliers from Europe or the US. Shifting gears to regulatory matters, recent developments highlight a dynamic industry characterized by scientific advancements, regulatory shifts, legal battles, and strategic corporate maneuvers. Central to these is the call for enhanced transparency and evidence standards in the FDA's accelerated approval pathway. Strengthening evidence requirements aims to ensure that drugs approved under this pathway are supported by robust scientific data, ultimately safeguarding patient health and maintaining public trust in regulatory institutions. A landmark financial event has unfolded with Kailera Therapeutics' record-breaking IPO, raising $625 million to bolster its obesity treatment pipeline. This significant capital inflow not only sets a new benchmark for biotech IPOs but also underscores burgeoning interest in addressing obesity—an area with substantial unmet medical needs. In legal arenas, Teva Pharmaceuticals scored a victory as an appeals court revived a $177 million verdict against Eli Lilly concerning patent disputes over migraine medications. Additionally, Viatris and Teva have initiated recalls due to issues with drug dissolution and raw material approvals. The appointment of Dr. Erica Schwartz as the potential Director of the CDC marks another pivotal moment. Her leadership could steer the CDC towards more effective public health responses. On a broader industry scale, there is anSupport the show

From the cities of the Dominican Republic to the streets of Washington Heights to the heart of Brooklyn's most dangerous neighborhoods, this is the untold story of Adam Diaz — a teenage immigrant who rose to become one of New York's most powerful cocaine kingpins. By just 18 years old, Diaz had already made his first million. Within a year, he was moving dozens of kilos a day through a network of bodegas, hidden stash houses, and underground tunnels — building an empire that generated millions of dollars weekly. His operation stretched across boroughs, fueled by direct connections to Colombian suppliers and protected by corruption at the highest levels, including ties to dirty NYPD officers. But behind the wealth, power, and influence was a world of constant violence, paranoia, and survival. Shootouts in broad daylight, rival crews, federal investigations, and betrayals from within — every move carried deadly consequences. This conversation dives deep into the rise, expansion, and eventual downfall of Adam Diaz's drug empire, revealing how the crack era, systemic corruption, and street economics created a perfect storm for one of the most explosive criminal careers of the 1980s. From million-dollar days to federal prison sentences, this is a raw and unfiltered look at ambition, risk, and the true cost of the drug game. Go Support Adam! https://kingofbrooklyn.weebly.com/ This Episode Is #Sponsored By The Following: Hims! To get simple, online access to personalized, affordable care for ED, Hair Loss, Weight Loss, and more, visit https://hims.com/connect Prescription required. See website for details and important safety information. Sildenafil is the generic version of Viagra®. Viagra® is a registered trademark of Viatris Specialty LLC. Hims is not affiliated with or endorsed by Viatris. Shopify! It's time to turn those “What Ifs” into with Shopify today. Sign up for your one-dollar-per-month trial today at https://shopify.com/mitchell Ava! Take control of your credit today. Download the Ava app, and when you join using MY promo code CONNECT20, you'll get 20% off your first year—monthly or annual, your choice. Join The Patreon For Bonus Content! https://www.patreon.com/theconnectshow 00:00 Adam Diaz's Rise: Making a Million at 18 02:00 From Dominican Republic to NYC: Early Life 05:30 Dominican Drug Dealers in New York 10:00 Washington Heights & NYC Drug Scene 16:58 This Episode Is Sponsored By Hims! 18:29 Getting into the Game: Family Ties 22:00 First Bodega Hustles and Street Fights 26:00 Taking Over the Drug Spot 29:40 This Episode Is Sponsored By Shopify! 31:56 Scaling Up: Building the Network 35:00 Supply Chains: Colombian Connections 41:00 The Bodega Operation: Logistics & Hidden Tunnels 47:00 Expansion: Multiple Bodegas, Factories & Staff 50:17 This Episode Is Sponsored By Ava! 51:39 Dealing with Cops and Corruption 01:00:00 Major Busts, Stick-Ups, and Surviving Shootouts 01:05:00 Wholesale Moves & Dealing with Competition 01:14:00 Importing Direct: Wanting to Be the Plug 01:18:00 Peak Operations: Moving Serious Weight 01:22:00 Paying Off Police & Dirty Cops in the Mix 01:27:00 Violence, Loyalty, and Surviving Attacks 01:34:00 Going Global: Importing and Losing Millions 01:43:00 The Fall: Getting Caught and Beating the Case 01:51:00 Court Drama and Plea Bargain 01:59:00 Family Reactions and Reflection 02:04:00 Sentencing and Aftermath 02:09:00 Present Day: Life After the Drug Game Learn more about your ad choices. Visit podcastchoices.com/adchoices

This episode covers: Cardiology this Week: A concise summary of recent studies What's new in hypertension? Why I favour a critical approach in cardiology Snapshots Host: Sabiha Gati Guests: Konstantinos Koskinas, Gianfranco Parati, John Mandrola, Yasmina Bououdina Want to watch this episode? Go to: https://esc365.escardio.org/event/2561 Disclaimer: ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Sabiha Gati, Nicolle Kraenkel and John Mandrola have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: honorary from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi.  Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Gianfranco Parati has declared to have potential conflicts of interest to report: Merck Sharp and Dohme, Omron Healthcare, Viatris. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Sabiha Gati Guest: Gianfranco Parati Want to watch this extended interview? Go to: https://esc365.escardio.org/event/2561?resource=interview Want to watch the episode? Go to: https://esc365.escardio.org/event/2561 Disclaimer: ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Sabiha Gati and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: honorary from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi.  Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Gianfranco Parati has declared to have potential conflicts of interest to report: Merck Sharp and Dohme, Omron Healthcare, Viatris. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

From the stages of Egypt to the global C-suite, Dr. Lobna Salem (CMO, Viatris) has always led with a "quiet courage". Join her and world-renowned pharmaceutical executive Dr. Amrit Ray as they discuss why the most effective leaders aren't just experts in their field—they are experts in humanity. This podcast is not available for CME/CE/CPD credits. Please visit the Medscape homepage for accredited CME/CE/CPD activities.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. In the ever-dynamic landscape of these industries, recent advancements have underscored both the scientific ingenuity and strategic foresight shaping patient care today.Pfizer has unveiled promising clinical trial data for Tukysa, indicating its potential as a first-line maintenance therapy in HER2-positive breast cancer. This development suggests that Tukysa could delay disease progression, offering patients extended survival prospects and an improved quality of life. Additionally, Pfizer's recent licensing agreement with Yaopharma for YP05002—a small molecule GLP-1 agonist currently in Phase 1 trials aimed at obesity treatment—highlights their strategic push into the rapidly evolving obesity treatment market.Meanwhile, Fondazione Telethon, an Italian nonprofit organization, has achieved a significant milestone with FDA approval for Waskyra—the first gene therapy for Wiskott-Aldrich syndrome. This ex vivo gene therapy directly targets the genetic roots of this rare disease, shifting treatment from symptomatic management to addressing underlying causes. This approval is transformative not only for patients suffering from this condition but also for the broader field of gene therapies, heralding a new era in treating rare genetic disorders.On the strategic front, Eli Lilly's decision to establish a $6 billion active pharmaceutical ingredient manufacturing facility in Huntsville, Alabama, marks a pivotal investment in U.S. manufacturing capabilities. This site will be critical in producing APIs for small molecule and peptide medicines, a testament to Lilly's commitment to meeting growing therapeutic demands while bolstering domestic production resilience—a trend gaining momentum across the industry. In oncology, Eli Lilly's Jaypirca demonstrated an impressive reduction in disease progression during Phase 3 trials for chronic lymphocytic leukemia.Biocon's acquisition of Viatris' stake in their biosimilar subsidiary exemplifies the shifting dynamics within the biosimilars market. This move allows Biocon to consolidate its market position as biosimilars gain traction as cost-effective alternatives to branded biologics. Such strategic realignments are indicative of competitive maneuvering aimed at capturing greater market share and driving down healthcare costs.Roche has made strides with compelling results from its Phase 3 trial of giredestrant, an oral selective estrogen receptor degrader showing a 30% reduction in risk for invasive breast cancer recurrence or death. The significance of this development lies in offering an oral alternative to injectable treatments, potentially improving patient adherence and reshaping standard care protocols for hormone receptor-positive breast cancer. Furthermore, Roche has achieved another regulatory milestone with its monoclonal antibody Gazyvaro gaining EU approval for treating lupus nephritis following successful Phase 3 trials.Innovation continues unabated as Formation Bio forms a new subsidiary through a $605 million deal with Lynk Pharmaceuticals. By securing rights to a next-generation immunology asset, Formation Bio positions itself at the forefront of immunological research developments. Concurrently, BioNTech and Bristol Myers Squibb have reported positive results from Phase 2 trials of Pumitamig for triple-negative breast cancer—validating bispecific antibodies' efficacy within oncology.Collaborative efforts are also reshaping industry landscapes. Bora and Corealis have partnered to create an end-to-end contract development and manufacturing organization for oral solid dose drug development. This collaboration aims to streamline processes and provide scalable solutions through a single contracting source, reflecting a shift towards integrated service models that enhance efficiencySupport the show

 Chronic Obstructive Pulmonary Disease (COPD) is a group of lung diseases that cause airflow obstruction and other respiratory problems. There are various options for treating COPD, including the highly effective controller medication that helps improve a patient's lung function in the long-term. But as Antonio R. Anzueto, MD, professor of pulmonary and critical care at the University of Texas Health, San Antonio, explains, it is not easy for patients to use these medications. Listen as Dr. Anzueto and host Amy Attaway, MD, Cleveland Clinic, discuss the effectiveness of different COPD treatments, how COPD can affect other organs, and how AI might play into diagnosing COPD as technology advances. Support for this podcast is brought to you by Viatris and Theravance BioPharma. 

988: In this episode of Technovation, we feature a panel from the Metis Strategy Summit moderated by Metis Strategy's Co-Head of Executive Networks, Media, and Research Steven Norton, exploring how senior technology executives are aligning AI to their business strategy. Joining the conversation are Ryan Snyder, CIO of Thermo Fisher Scientific; Ramkumar Rayapureddy, CIO of Viatris; and Allen Fazio, CIO of Houlihan Lokey. Together, they share how their organizations are evolving from isolated AI pilots to holistic strategies grounded in business value, robust governance, and relentless data modernization. The panelists discuss the practical realities of establishing clear measurement frameworks, navigating the tension between centralized control and decentralized innovation, and leading cultural change as AI adoption accelerates across regulated and fast-moving industries.

Men’s Health Week. Sponsored by Vedafil®. Viatris Ltd, New Zealand This week is Men’s Health Week and we’re checking in with sexual health expert, Dr Alistair Somerville to uncover common sexual health challenges faced by men. - How common conditions like erection difficulties & low libido really are. - Practical information on getting help from your healthcare professional including treatment options. - Discuss the importance of adopting healthier habits for long-term well-being. Plus... - Labour is more popular than National right now. How? What have they done? Is hiding in plain sight the best approach from Labour? - David Farrar the man behind the poll and the sharpest political tool in the kit is with us to explain what’s going on. - And some Letters to the Editor! Website: https://www.rova.nz/home/podcasts/duncan-garner---editor-in-chiefInstagram: @DuncanGarnerpodcast TikTok: @DuncanGarnerpodcast -------------------------------------------- The information contained in this podcast and any statements made herein are for educational purposes only and are of a general nature. They do not constitute medical advice, diagnostic, or therapeutic recommendations. Please consult a healthcare professional for individual medical advice. All views expressed, and any scientific publications referenced, are provided for general informational purposes only , and do not imply endorsement by the sponsor, any publication author or publisher. Vedafil® (sildenafil citrate) 25 mg, 50 mg & 100 mg tablets, for erectile dysfunction (ED) treatment in adult men. Unfunded prescription medicine. Doctor and Pharmacy fees apply. Medicines have benefits & risks. Ask your doctor or qualified pharmacist if Vedafil® is right for you. Take as directed. If symptoms persist or side effects occur, see your healthcare professional. View the Consumer Medicine Information at www.medsafe.govt.nz. Vedafil® is a Viatris company trade mark, Viatris Limited, Auckland. TAPS NP22850.

Men’s Health Week. Sponsored by Vedafil®. Viatris Ltd, New Zealand This week is Men’s Health Week and we’re checking in with sexual health expert, Dr Alistair Somerville to uncover common sexual health challenges faced by men. - How common conditions like erection difficulties & low libido really are. - Practical information on getting help from your healthcare professional including treatment options. - Discuss the importance of adopting healthier habits for long-term well-being. Website: https://www.rova.nz/home/podcasts/duncan-garner---editor-in-chiefInstagram: @DuncanGarnerpodcast TikTok: @DuncanGarnerpodcast -------------------------------------------- The information contained in this podcast and any statements made herein are for educational purposes only and are of a general nature. They do not constitute medical advice, diagnostic, or therapeutic recommendations. Please consult a healthcare professional for individual medical advice. All views expressed, and any scientific publications referenced, are provided for general informational purposes only , and do not imply endorsement by the sponsor, any publication author or publisher. Vedafil® (sildenafil citrate) 25 mg, 50 mg & 100 mg tablets, for erectile dysfunction (ED) treatment in adult men. Unfunded prescription medicine. Doctor and Pharmacy fees apply. Medicines have benefits & risks. Ask your doctor or qualified pharmacist if Vedafil® is right for you. Take as directed. If symptoms persist or side effects occur, see your healthcare professional. View the Consumer Medicine Information at www.medsafe.govt.nz. Vedafil® is a Viatris company trade mark, Viatris Limited, Auckland. TAPS NP22850.

Men’s Health Week. Sponsored by Vedafil®. Viatris Ltd, New Zealand This week is Men’s Health Week and we’re checking in with my good mate Mark Sainsbury to talk about smoking & alcohol. - Look at how we think about smoking & drinking differently now. - Explore Mark’s personal thoughts on quitting smoking & reducing alcohol intake. - Discuss the importance of adopting healthier habits for long-term well-being. Website: https://www.rova.nz/home/podcasts/duncan-garner---editor-in-chiefInstagram: @DuncanGarnerpodcast TikTok: @DuncanGarnerpodcast -------------------------------------------- The information contained in this podcast and any statements made herein are for educational purposes only and are of a general nature. They do not constitute medical advice, diagnostic, or therapeutic recommendations. Please consult a healthcare professional for individual medical advice. All views expressed, and any scientific publications referenced, are provided for general informational purposes only , and do not imply endorsement by the sponsor, any publication author or publisher. Vedafil® (sildenafil citrate) 25 mg, 50 mg & 100 mg tablets, for erectile dysfunction (ED) treatment in adult men. Unfunded prescription medicine. Doctor and Pharmacy fees apply. Medicines have benefits & risks. Ask your doctor or qualified pharmacist if Vedafil® is right for you. Take as directed. If symptoms persist or side effects occur, see your healthcare professional. View the Consumer Medicine Information at www.medsafe.govt.nz. Vedafil® is a Viatris company trade mark, Viatris Limited, Auckland. TAPS NP22850.

Men’s Health Week. Sponsored by Vedafil®. Viatris Ltd, New Zealand This week is Men’s Health Week and we’re checking in with my good mate Mark Sainsbury to talk about smoking & alcohol. - Look at how we think about smoking & drinking differently now. - Explore Mark’s personal thoughts on quitting smoking & reducing alcohol intake. - Discuss the importance of adopting healthier habits for long-term well-being. Plus... - Hipkins needs to cut Te Pāti Māori loose if he wants any chance of winning the next election! It's clear his affiliation with the party is tanking his numbers - as seen in a recent poll of kiwi farmers and who they'd vote for. - Joining me to discuss this poll is Associate Minister of Agriculture, Andrew Hoggard. - And some Letters to the Editor! Website: https://www.rova.nz/home/podcasts/duncan-garner---editor-in-chiefInstagram: @DuncanGarnerpodcast TikTok: @DuncanGarnerpodcast -------------------------------------------- The information contained in this podcast and any statements made herein are for educational purposes only and are of a general nature. They do not constitute medical advice, diagnostic, or therapeutic recommendations. Please consult a healthcare professional for individual medical advice. All views expressed, and any scientific publications referenced, are provided for general informational purposes only , and do not imply endorsement by the sponsor, any publication author or publisher. Vedafil® (sildenafil citrate) 25 mg, 50 mg & 100 mg tablets, for erectile dysfunction (ED) treatment in adult men. Unfunded prescription medicine. Doctor and Pharmacy fees apply. Medicines have benefits & risks. Ask your doctor or qualified pharmacist if Vedafil® is right for you. Take as directed. If symptoms persist or side effects occur, see your healthcare professional. View the Consumer Medicine Information at www.medsafe.govt.nz. Vedafil® is a Viatris company trade mark, Viatris Limited, Auckland. TAPS NP22850.

Men’s Health Week. Sponsored by Vedafil®. Viatris Ltd, New Zealand This week is Men’s Health Week & we’re checking in with my good mate Mike King about anxiety and depression. - Everyday realities of living with anxiety & depression from someone who’s seen it. - Opening up the conversation to encourage a better understanding of mental health. - What support or small changes help people feel less alone. Website: https://www.rova.nz/home/podcasts/duncan-garner---editor-in-chiefInstagram: @DuncanGarnerpodcast TikTok: @DuncanGarnerpodcast -------------------------------------------- The information contained in this podcast and any statements made herein are for educational purposes only and are of a general nature. They do not constitute medical advice, diagnostic, or therapeutic recommendations. Please consult a healthcare professional for individual medical advice. All views expressed, and any scientific publications referenced, are provided for general informational purposes only , and do not imply endorsement by the sponsor, any publication author or publisher. Vedafil® (sildenafil citrate) 25 mg, 50 mg & 100 mg tablets, for erectile dysfunction (ED) treatment in adult men. Unfunded prescription medicine. Doctor and Pharmacy fees apply. Medicines have benefits & risks. Ask your doctor or qualified pharmacist if Vedafil® is right for you. Take as directed. If symptoms persist or side effects occur, see your healthcare professional. View the Consumer Medicine Information at www.medsafe.govt.nz. Vedafil® is a Viatris company trade mark, Viatris Limited, Auckland. TAPS NP22850.

Men’s Health Week. Sponsored by Vedafil®. Viatris Ltd, New Zealand This week is Men’s Health Week & we’re checking in with my good mate Mike King about anxiety and depression. - Everyday realities of living with anxiety & depression from someone who’s seen it. - Opening up the conversation to encourage a better understanding of mental health. - What support or small changes help people feel less alone. Plus... - He’s been jailed for 8 years for raping a young kiwi women - why is our system so hopelessly weak and how did this man get to stay here and why did the Greens support him? - And some Letters to the Editor! Website: https://www.rova.nz/home/podcasts/duncan-garner---editor-in-chiefInstagram: @DuncanGarnerpodcast TikTok: @DuncanGarnerpodcast -------------------------------------------- The information contained in this podcast and any statements made herein are for educational purposes only and are of a general nature. They do not constitute medical advice, diagnostic, or therapeutic recommendations. Please consult a healthcare professional for individual medical advice. All views expressed, and any scientific publications referenced, are provided for general informational purposes only , and do not imply endorsement by the sponsor, any publication author or publisher. Vedafil® (sildenafil citrate) 25 mg, 50 mg & 100 mg tablets, for erectile dysfunction (ED) treatment in adult men. Unfunded prescription medicine. Doctor and Pharmacy fees apply. Medicines have benefits & risks. Ask your doctor or qualified pharmacist if Vedafil® is right for you. Take as directed. If symptoms persist or side effects occur, see your healthcare professional. View the Consumer Medicine Information at www.medsafe.govt.nz. Vedafil® is a Viatris company trade mark, Viatris Limited, Auckland. TAPS NP22850.

Men’s Health Week. Sponsored by Vedafil®. Viatris Ltd, New Zealand This week is Men's Health Week and we’re checking up on my good mate Dave Letele who’ll be sharing his observations around the impact of living with weight and diet challenges. - How society can judge & shame people living with these health challenges. - Real stories about the emotional side of being told your health is being impacted. - How our support & understanding can change lives. Website: https://www.rova.nz/home/podcasts/duncan-garner---editor-in-chiefInstagram: @DuncanGarnerpodcast TikTok: @DuncanGarnerpodcast -------------------------------------------- The information contained in this podcast and any statements made herein are for educational purposes only and are of a general nature. They do not constitute medical advice, diagnostic, or therapeutic recommendations. Please consult a healthcare professional for individual medical advice. All views expressed, and any scientific publications referenced, are provided for general informational purposes only , and do not imply endorsement by the sponsor, any publication author or publisher. Vedafil® (sildenafil citrate) 25 mg, 50 mg & 100 mg tablets, for erectile dysfunction (ED) treatment in adult men. Unfunded prescription medicine. Doctor and Pharmacy fees apply. Medicines have benefits & risks. Ask your doctor or qualified pharmacist if Vedafil® is right for you. Take as directed. If symptoms persist or side effects occur, see your healthcare professional. View the Consumer Medicine Information at www.medsafe.govt.nz. Vedafil® is a Viatris company trade mark, Viatris Limited, Auckland. TAPS NP22850.

Men’s Health Week. Sponsored by Vedafil®. Viatris Ltd, New Zealand This week is Men's Health Week and we’re checking up on my good mate Dave Letele who’ll be sharing his observations around the impact of living with weight and diet challenges. - How society can judge & shame people living with these health challenges. - Real stories about the emotional side of being told your health is being impacted. - How our support & understanding can change lives. Plus... - Tākuta Ferris' new private members bill is deeply concerning and frankly, quite crazy. Let's break it down. - Plus some Letters to the Editor Website: https://www.rova.nz/home/podcasts/duncan-garner---editor-in-chiefInstagram: @DuncanGarnerpodcast TikTok: @DuncanGarnerpodcast -------------------------------------------- The information contained in this podcast and any statements made herein are for educational purposes only and are of a general nature. They do not constitute medical advice, diagnostic, or therapeutic recommendations. Please consult a healthcare professional for individual medical advice. All views expressed, and any scientific publications referenced, are provided for general informational purposes only , and do not imply endorsement by the sponsor, any publication author or publisher. Vedafil® (sildenafil citrate) 25 mg, 50 mg & 100 mg tablets, for erectile dysfunction (ED) treatment in adult men. Unfunded prescription medicine. Doctor and Pharmacy fees apply. Medicines have benefits & risks. Ask your doctor or qualified pharmacist if Vedafil® is right for you. Take as directed. If symptoms persist or side effects occur, see your healthcare professional. View the Consumer Medicine Information at www.medsafe.govt.nz. Vedafil® is a Viatris company trade mark, Viatris Limited, Auckland. TAPS NP22850.

Men’s Health Week. Sponsored by Vedafil®. Viatris Ltd, New Zealand This week is Men’s Health Week & we’re checking up with my good mate Tai Matai; his story honestly told. Hear how he experienced the early warning signs of a heart attack. He’ll share how the event reshaped his approach to everyday life. How he’s now encouraging a reflection on men’s health & getting regular check-ups Plus... We need to delve into the truth about men's health in New Zealand. Men get a raw deal when it comes to health and it's time to talk about it. Also, Health Coach and former broadcaster Kent Johns joins us to discuss how us Kiwis can improve our own health. And some Letter's to the Editor! Website: https://www.rova.nz/home/podcasts/duncan-garner---editor-in-chiefInstagram: @DuncanGarnerpodcast TikTok: @DuncanGarnerpodcast -------------------------------------------- The information contained in this podcast and any statements made herein are foreducational purposes only and are of a general nature. They do not constitute medicaladvice, diagnostic, or therapeutic recommendations. Please consult a healthcareprofessional for individual medical advice. All views expressed, and any scientificpublications referenced, are provided for general informational purposes only , and donot imply endorsement by the sponsor, any publication author or publisher. Vedafil® (sildenafil citrate) 25 mg, 50 mg & 100 mg tablets, for erectile dysfunction (ED)treatment in adult men. Unfunded prescription medicine. Doctor and Pharmacy fees apply. Medicines have benefits & risks. Ask your doctor or qualified pharmacist if Vedafil® is right for you. Take as directed. If symptoms persist or side effects occur, see your healthcare professional. View the Consumer Medicine Information at www.medsafe.govt.nz. Vedafil® is a Viatris company trade mark, Viatris Limited, Auckland. TAPS NP22850.

Men’s Health Week. Sponsored by Vedafil®. Viatris Ltd, New Zealand This week is Men’s Health Week & we’re checking up with my good mate Tai Matai; his story honestly told. Hear how he experienced the early warning signs of a heart attack. He’ll share how the event reshaped his approach to everyday life. How he’s now encouraging a reflection on men’s health & getting regular check-ups Website: https://www.rova.nz/home/podcasts/duncan-garner---editor-in-chiefInstagram: @DuncanGarnerpodcast TikTok: @DuncanGarnerpodcast -------------------------------------------- The information contained in this podcast and any statements made herein are foreducational purposes only and are of a general nature. They do not constitute medicaladvice, diagnostic, or therapeutic recommendations. Please consult a healthcareprofessional for individual medical advice. All views expressed, and any scientificpublications referenced, are provided for general informational purposes only , and donot imply endorsement by the sponsor, any publication author or publisher. Vedafil® (sildenafil citrate) 25 mg, 50 mg & 100 mg tablets, for erectile dysfunction (ED)treatment in adult men. Unfunded prescription medicine. Doctor and Pharmacy fees apply. Medicines have benefits & risks. Ask your doctor or qualified pharmacist if Vedafil® is right for you. Take as directed. If symptoms persist or side effects occur, see your healthcare professional. View the Consumer Medicine Information at www.medsafe.govt.nz. Vedafil® is a Viatris company trade mark, Viatris Limited, Auckland. TAPS NP22850.

This week's episode dives into COPD treatment. When considering inhaler devices, what is the best strategy for COPD patients? Host Amy Attaway, MD, MS, associate director of the COPD Center at  Cleveland Clinic welcomes Anthony Anzueto, MD, professor of medicine at the University of Texas Health Science Center and chief of the pulmonary section for the South Texas Veterans Healthcare System in San Antonio.Support for this podcast is brought to you by Viatris and Theravance BioPharma.

Live from Mix and Mingle Education Day: A Powerful Conversation with CaregiversIn this deeply moving live episode recorded at the Mix and Mingle Education Day, we brought together a powerful group of caregivers—grandparents, parents, stepparents, dads, and friends—for a heartfelt discussion about the emotional journey of caring for a loved one with cystic fibrosis.What started as a simple idea to gather voices turned into our most beautiful and emotional podcast yet. There were tears, laughter, and unforgettable stories. We were honored to be joined by a Grief Counselor who helped guide us through the complex feelings that surfaced during our conversation.This episode is a raw, real, and uplifting tribute to the strength, vulnerability, and love that caregivers bring to their roles every single day.Join us for a conversation that honors the heart of caregiving and the power of community.You'll hear from:(00:00:00) Laura Bonnell - Host - (Egypt, Foundation programs, legislation)(00:16:49)  Lois Teicher - CF Grandmother (Laura's Mom) (00:19:05)  Natalie Wicks Lois's partner(00:21:36) Julie Weatherhead - Grief Doula(00:28:45)  Sharon Tischio - CF Mom(00:33:08) Cambria Whitaker - CF Mom in a queer/transgender relationship(00:38:55) Theresa Dagget, MSU Clinic, Respiratory Therapist, CF coordinator(00:49:00 ) Dorothy Stratford,CF Family Caregiver(00:52:15) Jillian Rogers Smith, 33 year old CF Patient and Dad, Bill Rogers (01:01:40) CF Mom to 6 year old daughter Louisa(01:07:28) Wendi Tague (Nurse Coordinator) and Claire Haglund (Social Worker) Present but not on the microphone were Joe Bonnell (Laura's husband), Jeannette Bovensie (Dorothy's Mom) and Dani Nettleton and daughter.Claire Haglund: CHaglund@dmc.orgWendi Tague: wtague@dmc.orgLois Teicher (Laura's Mom): Loisteicher@yahoo.comNatalie Wicks: Piccolo35@gmail.comTheresa Daggett: daggett3@msu.eduCambria Whittaker: cambriawhitta@gmail.comDorothy Straford: dstrat701@gmail.comSharon Tischio: stischio@comcast.netJamie Rudnycky: jamie.rudnycky@gmail.comJulie Weatherhead: weathervanecounseling@gmail.comJillian Smith, Jillian's Jay Walkers: jill@jilliansjaywalkers.org   And Jillian's Dad, Bill Rogers Please like, subscribe, and comment on our podcasts!Please consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website:https://thebonnellfoundation.orgEmail us at: thebonnellfoundation@gmail.com Watch our podcasts on YouTube: https://www.youtube.com/@laurabonnell1136/featuredThanks to our sponsors:Vertex: https://www.vrtx.comViatris: https://www.viatris.com/en

This episode covers: Cardiology This Week: A concise summary of recent studies Hypertension in the elderly The digital twin in cardiology Snapshots Host: Emer Joyce Guests: Carlos Aguiar, Gianfranco Parati, Nico Bruining, Joost Lumens Want to watch that episode? Go to: https://esc365.escardio.org/event/1804 Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests: Stephan Achenbach, Nico Bruining, Emer Joyce and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Joost Lumens has declared to have potential conflicts of interest to report: research grants from Medtronic (all grants paid to institute, Maastricht University). Gianfranco Parati has declared to have potential conflicts of interest to report: honoraria for lectures by Omron, Merck, Viatris, Somnomedics. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Join Isabel and Jade as they wrap up Season 9 of the podcast with special guest Dennise Broderick, President and Managing Director, Galen Pharma.  In this episode, Jade and Dennise discuss her move from academia to the pharmaceutical industry, her lifelong ambition to be a leader and how she approaches hard decisions in business.  A little more on EMJ GOLD's guest… Dennise is Managing Director and President at Galen – a pharmaceutical company based in Northern Ireland focused on pain management, dermatology and gastroenterology. There, she is responsible for all the aspects of the company's operations, marketing and governance across its various sites throughout the UK and Europe. Previously, Dennise has held positions at Pfizer, Hospira, Zeneus and Viatris – most recently working as the Country Manager at Ipsen. 

This episode covers: Cardiology This Week: A concise summary of recent studies Relevance and management of ventricular ectopic beats  Lp(a) in cardiovascular risk management Mythbusters: A vegetarian diet lowers cardiovascular risk Host: Susanna Price Guests: Carlos Aguiar, Thomas Deneke, Kausik Ray Want to watch that episode? Go to: https://esc365.escardio.org/event/1802 Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests: Stephan Achenbach, Thomas Deneke, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Kausik Ray declared to have potential conflicts of interest to report: research grants from Amarin, Amgen, Daiichi Sankyo, Merck Sharp & Dohme, Pfizer, Regeneron, and Sanofi, consultant for Abbott, Amarin, Amgen, AstraZeneca, Bayer, Biologix, Boehringer Ingelheim, Cargene Therapeutics, CRISPR, CSL Behring, Eli Lilly and Company, Esperion, Kowa Pharmaceuticals, NewAmsterdam Pharma, Novartis, Novo Nordisk, Pfizer, Regeneron, Resverlogix, Sanofi, Scribe Therapeutics, Silence Therapeutics, Vaxxinity, and Viatris, honoraria for lectures from Novartis, BI, AZ, Novo Nordisk, Viatris, Amarin, Biologix Pharma, Sanofi, Amgen, Esperion, Daiichi Sankyo, Macleod and stock options New Amsterdam Pharma, Pemi 31, SCRIBE Therapeutics. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: New drug is looked at for T1D prevention, a new stem cell method is tested for beta cell transplanation without immunosuppresion drugs, the FDA okays the first fast-acting biosimilar insulin, Lilly lowers price of Zepbound, and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens  Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX New research in type 1 diabetes prevention launches. Nektar Therapeutics and TrialNet will evaluate a drug currently used for exzema for patients with new onset stage 3 type 1 diabetes The drug is RezPeg – that's a shortened version of the name (rezpegaldesleukin)   This will be a study of about 70 adults and children and will launch this year. The new study will use a mixed meal tolerance test (MMTT) to measure the efficacy of rezpegaldesleukin or placebo for preserving C-peptide area under the curve over a 12-month duration comprised of a 6-month treatment period and a 6-month follow-up. Secondary objectives include pharmacokinetics, pharmacodynamics, and additional disease assessments including HbA1c levels and patient insulin requirements. Rezpegaldesleukin is being developed as a self-administered injection for a number of autoimmune and inflammatory diseases. https://www.prnewswire.com/news-releases/nektar-announces-clinical-trial-agreement-to-evaluate-rezpegaldesleukin-in-patients-with-new-onset-type-1-diabetes-mellitus-302383052.html XX NLS Pharmaceutics (NLSP) and Kadimastem announced successful completion of a pre-IND meeting with the FDA for iTOL-102, a potential diabetes treatment. iTOL-102 combines Kadimastem's IsletRx cells (stem cell-derived pancreatic islets) with iTolerance's immunomodulator iTOL-100, aiming to cure Type 1 Diabetes without requiring life-long immune suppression. The treatment was evaluated at the Diabetes Research Institute at the University of Miami School of Medicine, where it demonstrated functional insulin release and disease reversal in animal models. Based on FDA feedback, the companies are updating plans for safety toxicology studies and First-in-Human clinical trials. IsletRx is a clinical-grade product comprising human pancreatic islet-like cells capable of secreting insulin, offering a scalable source of insulin-producing cells to address donor islet shortages. The technology can detect glucose levels and produce required amounts of insulin and glucagon.   XX FDA has signed off on a rapid-acting insulin biosimilar for the first time. The agency has given a thumbs up to Sanofi's Merilog (insulin-aspart-szjj) as the first biosimilar to Novo Nordisk's NovoLog for patients with diabetes. Merilog will be provided by prefilled pen in a 3 mL dose or in a multiple-dose 10 mL vial. It is for adults and pediatric patients age 6 and older.     NovoLog and Novo Nordisk's other rapid-acting insulin follow-on Fiasp are among the drugs subject to government price negotiations under the Inflation Reduction Act. The new prices will be enacted at the start of next year. In July 2021, the FDA approved Biocon and Viatris' Semglee (insulin glargine-yfgn) as the first biosimilar to Lantus. Five months later, the U.S. regulator endorsed Eli Lilly's version of the drug, called Rezvoglar (insulin glargine-aglr). https://www.fiercepharma.com/pharma/fda-signs-sanofis-biosimilar-first-novo-nordisks-rapid-acting-novolog XX Eli Lilly said Tuesday that it will offer more doses of its obesity drug Zepbound in vials and lower the prices of the doses it already sells, as the pharma giant seeks to draw patients away from cheap, compounded copies of weight loss medications. The company launched 7.5 mg and 10 mg vials of tirzepatide, sold under the brand name Zepbound, which typically cost $599 and $699, respectively. However, they are now available for $499 per month for patients paying without insurance. This applies to the first fill and all refills that are delivered every 45 days. Additionally, the company lowered the prices of the 2.5 mg and 5 mg vials to $349 and $499 per month, respectively. The company, which has seen a significant boost in profits from Zepbound and Mounjaro – essentially the same drug with different FDA-approved uses – announced that the new vials and pricing are exclusively available through the company's self-pay pharmacy, LillyDirect Self Pay Pharmacy Solutions. https://www.bloomberg.com/news/articles/2025-02-25/zepbound-cost-for-vials-cut-to-battle-cheaper-copycats XX Medicare spending on 10 diabetes drugs, including popular GLP-1s, more than quadrupled over a five-year period and could reach $102 billion next year, an analysis by Health and Human Services' inspector general found. The findings also come as the Trump administration weighs the fate of a Biden administration proposal that would require Medicare and Medicaid to cover GLP-1s for weight loss. The biggest spikes in usage were for Rybelsus, Novo Nordisk's once-daily GLP-1 tablet, and for the company's weekly injectable Ozempic, whose spending about doubled every year under review. https://www.axios.com/2025/02/25/medicare-spending-surge-diabetes-drugs XX Tandem Diabetes Care has secured a new FDA clearance for its insulin dose-calculating algorithm, opening up Control IQ for use in adults with Type 2 diabetes. The expanded label was based on data from a pivotal, randomized trial of more than 300 people with Type 2 diabetes, comparing its use to manual multiple daily injections. Tandem said it plans to present the study's results at the annual Advanced Technologies & Treatments for Diabetes meeting scheduled for next month in Amsterdam. https://www.fiercebiotech.com/medtech/tandem-diabetes-care-insulin-dosing-algorithm-nets-fda-clearance-type-2-diabetes XX Drugs approved for diabetes and obesity might be useful for the treatment of cognitive and mental health disorders, according to a new paper published in Nature Mental Health.   The study reviewed and integrated data from both preclinical and clinical studies to gather evidence on the possible effects of these drugs GLP1s and semaglutide  in conditions such as dementia, substance use disorders, psychotic disorders, mood and anxiety disorders, and eating disorders.     The study found promising but still preliminary evidence that GLP-1RAs could be beneficial over a range of cognitive and mental health disorders. These drugs have shown potential in improving cognition, reducing addictive behavior, and alleviating depression and anxiety. More data from robustly designed studies (i.e., randomized controlled trials) are needed to better understand GLP-1RAs' prospective efficacy and safety profile, especially with long-term use. https://medicalxpress.com/news/2025-02-diabetes-drugs-mental-health-treatment.html XX The FDA  issued draft guidance that includes recommendations to support the development and marketing of safe and effective AI-enabled The guidance, if finalized, would be the first guidance to provide comprehensive recommendations for AI-enabled devices throughout the total product lifecycle, providing developers with an accessible set of considerations that tie together design, development, maintenance, and documentation recommendations to help ensure the safety and effectiveness of AI-enabled devices. FDA is requesting public comment on this draft guidance by April 7. The agency also released draft guidance for the use of AI to support regulatory decision-making for drug and biological products. https://www.mddionline.com/artificial-intelligence/fda-issues-draft-guidance-for-ai-enabled-devices-seeks-public-feedback XX Congrats to Mila Clarke who some of you may know better as Hangry Woman on social. She has developed a great app called Glucose Guide and the Nutrition Assistant portion of that app went live this week. Glucose Guide is a web and mobile app that offers diabetes meal tracking, coaching, resources, recipes and community to those looking for help managing diabetes. MEAL AND BLOOD SUGAR TRACKING FEATURES.

This podcast was supported by Viatris. The views and opinions expressed in this podcast are those of the individual speakers and do not necessarily reflect those of Viatris or EMJ. Speakers have received honoraria for their participation. Explore the challenges and solutions for managing opioid-induced constipation (OIC) in this insightful podcast, featuring discussions from a leading gastroenterologist and an expert pain specialist. Topics covered include: Defining OIC prevalence, underlying mechanisms, and impact on patient wellbeing The risks and limitations of laxative use in managing OIC The role of peripherally acting mu-opioid receptor antagonists Strategies for improved communication and monitoring

Disease-modifying therapies work, and, as a result, people with MS are living longer. With half the MS population over the age of 55, it's never been more urgent to understand how the process of aging impacts MS and how MS impacts the process of aging. In this special episode of RealTalk MS, Dr. Leorah Freeman discusses the many factors associated with aging with MS. This special episode of RealTalk MS is sponsored by Viatris. SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/V202 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com Join the RealTalk MS Facebook Group https://facebook.com/groups/realtalkms Download the RealTalk MS App for iOS Devices https://itunes.apple.com/us/app/realtalk-ms/id1436917200 Download the RealTalk MS App for Android Deviceshttps://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode V202 Guests: Dr. Leorah Freeman Privacy Policy

Transforming Your Mental Health Journey with MS- Episode 179 - Transcript Join host Dr. Stephanie Buxhoeveden with guest neuropsychologist Meghan Beier, who joins us to dive deeper into how various therapeutic approaches can transform your mental health journey with MS. Whether you're living with MS or a care partner, you'll find helpful explanations of different therapies and actionable insights that can empower you on your journey. If you're here looking for support, education, or inspiration, this episode is here to help you build resilience, live well, and thrive with MS. Thank you to Viatris for their support of this podcast episode. Disclaimer: This podcast provides general educational information. Can Do MS does not endorse, promote, or recommend any product, service, or diet associated with the content of this program.

Increased restrictions for HRT menopause treatment, as Pharmac finds ways shore up supply of oestradiol patches. It's changing its main funded brand to Estradiol TDP Mylan from supplier Viatris from next July. In order to ensure supply, it'll be the only funded brand available by December 2025. Menodoctor Clinical Director, Linda Dear, says those who can't use the Mylan brand will have other options. "Most women who get on with other, non-Mylan brands will get on with gel fine - but it means they'll have to start probably thinking about that transition." LISTEN ABOVESee omnystudio.com/listener for privacy information.

MS affects almost 3 times as many women as men, often affecting women of childbearing age. In this special episode of RealTalk MS, Dr. Riley Bove answers some of the important questions about the impact of MS on a woman's pregnancy and the impact of pregnancy on a woman's MS. This special episode of RealTalk MS is sponsored by Viatris. SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/V201 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com Join the RealTalk MS Facebook Group https://facebook.com/groups/realtalkms Download the RealTalk MS App for iOS Devices https://itunes.apple.com/us/app/realtalk-ms/id1436917200 Download the RealTalk MS App for Android Deviceshttps://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode V201 Guests: Dr. Riley Bove Privacy Policy

October 28, 2024Season 6 | Episode 39Unlock the secrets of an ancient tradition's surprising link to stock market success. Discover how the Halloween strategy could transform your investing game, along with an intriguing peek into the origins of Halloween itself. We'll dive into the heart of the market's pulse, from the S&P 500's "Magnificent 7" to undervalued gems waiting to be discovered as earnings season heats up. Join Brad and the team as we navigate the twists and turns of global events and their ripple effects on financial markets, from oil price shifts driven by geopolitical tensions to the political stage's influence on indices.Explore the unpredictable dance of the bond market and how it might impact your wallet, especially if you're dealing with variable rate debt. We'll uncover the stories of companies like Ford, defying expectations, and examine the significance of bond market volatility and its historical echoes. As the political landscape looms large, we caution against making hasty investment choices based on election predictions and instead spotlight undervalued opportunities like Viatris. Whether you're a seasoned investor or just curious about the financial world, this episode promises a well-rounded snapshot of the economic landscape and potential pathways to profit.** For informational and educational purposes only, not intended as investment advice. Views and opinions are subject to change without notice. For full disclosures, ADVs, and CRS Forms, please visit https://heroldlantern.com/disclosure **To learn about becoming a Herold & Lantern Investments valued client, please visit https://heroldlantern.com/wealth-advisory-contact-formFollow and Like Us on Youtube, Facebook, Twitter, and LinkedIn | @HeroldLantern

Luis Herrero entrevista a Joao Madeira, presidente de la Fundación Viatris para la Salud.

Want to support Global Value? https://www.interactivebrokers.com/mkt/?src=gvy1&url=%2Fen%2Fwhyib%2Foverview.php https://www.patreon.com/GlobalValue David Einhorn owns 42 stocks in his portfolio worth 2.2 billion dollars. In this video we're covering his top 10 biggest positions. Starting with #10 Viatris. David Einhorn is the founder and president of Greenlight Capital, a "long-short value-oriented hedge fund" he started in 1996. Over the next decade, the fund returned 26% annually, easily beating the market. He receives extensive coverage in the financial press for his fund's performance, his investing strategy and his positions. Einhorn was included in Time magazine's Time 100 list of "100 most influential people in the world" in 2013. According to Investopedia, his net worth was around US$1.5 billion in June 2019. Thank you for watching. ❤️ Please support the channel by checking out our affiliates. All commissions are reinvested to improve the quality of videos! - TIKR is the website I use for financial data in my videos. Join me and 250,000+ investors worldwide by using TIKR in your investment analysis. Referral link - https://www.tikr.com/globalvalue - Check out Seeking Alpha Premium and score an exclusive 20% off plus a free 7 day trial! Affiliate link - https://www.sahg6dtr.com/H4BHRJ/R74QP/ - Try Sharesight https://www.sharesight.com/globalvalue (remember you get 4 months free if you sign up for an annual subscription!) #davideinhorn #davideinhornportfolio #davideinhornstocks #greenlightcapital #greenlightportfolio #stocks2024 #stockmarket2024 #macro #superinvestors #investing2024 #investing #stockportfolio #portfolio #portfoliodeepdive #greenlightstocks

Want to support Global Value? https://www.interactivebrokers.com/mkt/?src=gvp1&url=%2Fen%2Fwhyib%2Foverview.php https://www.patreon.com/GlobalValue David Einhorn owns 42 stocks in his portfolio worth 2.2 billion dollars. In this video we're covering his top 10 biggest positions. Starting with #10 Viatris. David Einhorn is the founder and president of Greenlight Capital, a "long-short value-oriented hedge fund" he started in 1996. Over the next decade, the fund returned 26% annually, easily beating the market. He receives extensive coverage in the financial press for his fund's performance, his investing strategy and his positions. Einhorn was included in Time magazine's Time 100 list of "100 most influential people in the world" in 2013. According to Investopedia, his net worth was around US$1.5 billion in June 2019. Thank you for watching. ❤️ Please support the channel by checking out our affiliates. All commissions are reinvested to improve the quality of videos! - TIKR is the website I use for financial data in my videos. Join me and 250,000+ investors worldwide by using TIKR in your investment analysis. Referral link - https://www.tikr.com/globalvalue - Check out Seeking Alpha Premium and score an exclusive 20% off plus a free 7 day trial! Affiliate link - https://www.sahg6dtr.com/H4BHRJ/R74QP/ - Try Sharesight https://www.sharesight.com/globalvalue (remember you get 4 months free if you sign up for an annual subscription!) #davideinhorn #davideinhornportfolio #davideinhornstocks #greenlight #greenlightportfolio #stocks2024 #stockmarket2024 #hedgefund #stocks #superinvestors #investing2024 #investing #stockportfolio #portfolio #portfoliodeepdive #investmentstrategies

Mick Barry TD chats to Gareth O'Callaghan following the announcement that Viatris is too close it's Little Island plant Hosted on Acast. See acast.com/privacy for more information.

The stats for the percentage of men with erectile dysfunction are pretty staggering:Approximately 41.5% of men in the UK reported experiencing ED, according to a 2018 study conducted by Viatris, Queen's University Belfast, and Pfizer. And it only increases with age: - Around 29.3% for men aged 18-39 - About 45.6% of men aged 40 and overAccording to research by the British Association of Urological Surgeons, 50-55% of British men between 40 and 70 years old have some degree of ED. Ken Schafer can count himself as one of those men who also struggled with ED, and, like many men, he went straight for Viagra to cure his problem. After some time, that failed to work, so he started to look for other solutions. His journey led him to write a book, ‘A Practical Guide to Managing Erectile Dysfunction' and to help now men like himself struggling with ED. In particular, he signposts his clients to specific practitioners who can support them in becoming more fit and healthy and, as a result, remove the requirement for pharmaceuticals and other medical interventions.I found Ken's honesty and willingness to be vulnerable about this particular challenge with ED very refreshing. And if you have a title for his job, please share it with me!Web: https://www.healthysexualitywithken.com/Social media:https://www.instagram.com/healthys3xualitywithken/https://www.tiktok.com/@healthys3xualitywithkenhttps://www.youtube.com/@HealthySexualityWithKenLLChttps://www.facebook.com/healthys3xualitywithkenllchttps://twitter.com/HSWKen Get full access to Sex Advice for Seniors at www.sexadviceforseniors.com/subscribe

ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly.   This episode covers: Cardiology This Week: A concise summary of recent studies State-of-affairs in hypertension treatment Anticoagulation in pregnancy Statistics Made Easy : Accuracy and AUC    Host: Perry Elliott Guests: Carlos Aguiar, Gianfranco Parati, Julie De Backer Want to watch that episode? Go to: https://esc365.escardio.org/event/1152   Disclaimer This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.   Declarations of interests Stephan Achenbach, Julie De Backer and Nicolle Kraenkel have declared to have no potential conflicts of interest to report.  Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, Lilly, Novartis, Pfizer, Sanofi, Servier, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Novo Nordisk, Sanofi. Terumo, Medtronic. Perry Elliott has declared to have potential conflicts of interest to report: consultancies for Pfizer, BMS, Cytokinetics. Gianfranco Parati has declared to have potential conflicts of interest to report: honoraria for lectures by Omron, Viatris, Merck, Recor, Somnomedics. Emma Svennberg has declared to have potential conflicts of interest to report: institutional research grants from Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Boehringer-Ingelheim, Johnson & Johnson, Merck Sharp & Dohme.

About Dr. Bollinger Dr. Bollinger is a board-certified optometrist and a Fellow of the American Academy ofOptometry which demonstrates her commitment to excellence and lifelong learning inher profession. She has participated in advisory board meetings & also as a KeyOpinion Leader for companies such as Alcon, Ocular Therapeutix, Novartis, ScienceBased Health, Viatris, and TearScience. She enjoys educating which allows herto share her passion and expertise on dry eye and ocular surgery with other eye careprofessionals and the public. She earned her undergraduate degree in Biology at MiamiUniversity in Ohio and her Doctor of Optometry degree at Ohio State University. Sheserved as an adjunct clinical professor at Ohio State University from 2006-2012. Shehas participated as a clinical investigator in several FDA pharmaceutical and surgicalstudies for dry eye disease, presbyopia, topical steroids, intraocular lenses, andDemodex blepharitis. Her primary career goal is to help patients achieve optimal visionand eye health through personalized and evidence-based care.As an optometrist with 30+ years of experience, she strives to provide exceptional eyecare to patients with various ocular conditions and needs. She has extensiveexperience in perioperative surgical eye care, managing thousands of cases ofrefractive, cataract, and cornea surgeries throughout her career. Dr. Bollinger is alsoskilled in medical eye care, treating patients with glaucoma, diabetes, maculardegeneration, and dry eyes. Helping patients with ocular surface disease, including dryeye, meibomian gland disease, & blepharitis is her primary passion. She currently sees patients at Jacksoneye in Lake Villa, Illinois.

Professors Wytske Fokkens and Joaquim Mullol discuss the burden of smell loss and the emerging science on how inflammation drives olfactory dysfunction in patients with CRSwNP. ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com. This podcast is intended for healthcare professionals only. Disclaimer:  This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures: Professor Wytske Fokkens, MD, PhD has received consultation/speaker fees from Novartis, Sanofi, GSK and Dianosic.  Professor Joaquim Mullol, MD, PhD reports have received research grants, participated in clinical trials, been a member of Speaking Bureaus and Advisory Boards from Allakos, AstraZeneca, Glenmark, GSK, Menarini, MSD, Mitsubishi-Tanabe, Noucour/Uriach Group, Novartis, Optinose, Proctor & Gamble, Sanofi-Genzyme, Regeneron Pharmaceuticals, Viatris. © 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2400013 v1.0 01/2024 MAT-US-24000221 v1.0 - P Expiration Date: 01/08/2026